Firouzé Bani-Sadr

Firouzé Bani-Sadr

Auto-generated profile, based on publicly available information

Firouzé Bani-Sadr

Department of Internal Medicine, Clinical Immunology and Infectious Diseases, Reims University Hospital, Reims, France

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2006 in AIDS
Verified
Journal Article
Closed access
FBFirouzé Bani-Sadr
Firouzé Bani-Sadr
FCFabrice Carrat
Fabrice Carrat
PBPierre Bedossa
Pierre Bedossa
LPLionel Piroth
Lionel Piroth
PCPatrice CACOUB
Patrice CACOUB
SPStanislas Pol
Stanislas Pol
To evaluate the prevalence and severity of steatosis and possible interactions between steatosis, host factors, viral factors, and treatment for HIV infection in HIV-hepatitis C virus (HCV) coinfected patients. Steatosis was assessed among 395 HIV-HCV coinfected patients who were enrolled in the ANRS trial HC02 Ribavic and for whom histological data were available. Steatosis was graded as follows: 0 (none); 1 (< 30% hepatocytes containing fat); 2 (30-70%); 3 (> 70%). Steatosis was present in 241 patients (61%), of whom 149 (38%) had grade 1, 64 (16%) grade 2 and 28 (7%) grade 3. In multivariate analysis, the following five independent risk factors were associated with steatosis: HCV genotype 3 [odds ratio (OR), 3.02; 95% confidence interval (CI), 1.91-4.79; P < 0.0001], the mean METAVIR fibrosis score (OR, 1.43; 95% CI, 1.11-1.84; P = 0.0053), the body mass index (BMI; OR, 1.13; 95% CI, 1.05-1.21; P = 0.0013), HCV viral load (OR. 1.65; 95% CI, 1.22-2.23; P = 0.0012) and ferritin (OR, 1.13; 95% CI, 1.06-1.21; P < 0.0003). As HCV genotype 3 was a risk factor for steatosis, further exploratory analyses were stratified according to the HCV genotype (1 and 3). Factors independently associated with steatosis were BMI and HCV viral load in patients with HCV genotype 3 infection and the mean METAVIR fibrosis score, the BMI and ferritin in patients with HCV genotype 1 infection. Steatosis is particularly frequent in HIV-HCV coinfected patients, who appear to have the same risk factors for steatosis as HCV monoinfected patients. None of the characteristics of HIV infection, including antiretroviral therapy, was independently associated with steatosis.

1 September 2005 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
FBFirouzé Bani-Sadr
Firouzé Bani-Sadr
FCFabrice Carrat
Fabrice Carrat
SPStanislas Pol
Stanislas Pol
RHRavy Hor
Ravy Hor
EREric Rosenthal
Eric Rosenthal
CPChristian Perronne
Christian Perronne
To evaluate the incidence, clinical features, and risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus (HCV)-coinfected patients receiving anti-HCV therapy. All cases of symptomatic mitochondrial toxicity reported in 416 patients participating in an open, randomized trial of peg-interferon alpha-2b plus ribavirin vs. interferon alpha-2b plus ribavirin for 48 weeks were reviewed. Associations with antiretroviral treatments and with clinical and laboratory findings were sought by univariate and multivariate analysis. Eleven of the 383 patients who received at least 1 dose of anti-HCV treatment developed symptomatic mitochondrial toxicity (symptomatic hyperlactatemia and pancreatitis in 6 and 5 patients, respectively). All cases occurred in patients being treated for HIV infection, and the incidence of symptomatic mitochondrial toxicity was 47.5 per 1000 patient-years. In multivariate analysis, symptomatic mitochondrial toxicity was significantly associated with didanosine-containing antiretroviral regimens (odds ratio 46; 95% CI, 7.4 to infinity; P < 0.001), but not with stavudine or with nucleoside reverse transcriptase inhibitor regimens not containing didanosine. The incidence of symptomatic mitochondrial toxicity was 200.2 per 1000 patient-years in patients receiving didanosine. Demographic characteristics were not associated with symptomatic mitochondrial toxicity. Coadministration of ribavirin with didanosine should be avoided. If unavoidable, patients should be monitored closely for mitochondrial toxicity. Didanosine should be suspended if clinical signs or symptoms of mitochondrial toxicity occur.

1 March 2008 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
FBFirouzé Bani-Sadr
Firouzé Bani-Sadr
NLNathanael Lapidus
Nathanael Lapidus
PBPierre Bedossa
Pierre Bedossa
CBCorinne Merle De Boever
Corinne Merle De Boever
CPChristian Perronne
Christian Perronne
TTthe French National Agency for Research on AIDS and Viral Hepatitis--HC02--Ribavic Study Team
the French National Agency for Research on AIDS and Viral Hepatitis--HC02--Ribavic Study Team
Background. We determined the prevalence and determinants of worsening fibrosis in patients coinfected with human immunodeficiency virus (HIV) and he

1 October 2004 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
FBF. Bani‐Sadr
F. Bani‐Sadr
PPP. Palmer
P. Palmer
CSC. Scieux
C. Scieux
JMJ. M. Molina
J. M. Molina
We describe 6 patients who were coinfected with human immunodeficiency virus (HIV) type 1 and wild-type hepatitis B virus (HBV), in whom complete and sustained antiviral activity against wild-type HBV strains was attained during 96 weeks of combination therapy with lamivudine and tenofovir. The use of combination therapy with lamivudine and tenofovir for the treatment of HBV infection is very promising in the treatment of HIV/HBV coinfection.

15 December 2005 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
FBFirouzé Bani-Sadr
Firouzé Bani-Sadr
FCFabrice Carrat
Fabrice Carrat
EREric Rosenthal
Eric Rosenthal
LPLionel Piroth
Lionel Piroth
PMPatrice Morand
Patrice Morand
CPChristian Perronne
Christian Perronne
Spontaneous hepatic decompensation was observed in 7 of 383 patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) w

1 August 2020 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
FBFirouzé Bani-Sadr
Firouzé Bani-Sadr
MHMaxime Hentzien
Maxime Hentzien
MPMadeline Pascard
Madeline Pascard
YNYohan N'GUyen
Yohan N'GUyen
ASAmélie Servettaz
Amélie Servettaz
DJDamien Jolly
Damien Jolly